Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to main content

The Backstory

concentration-ranges

As we reported in October 2017, the use of prescribed concentration ranges, as required under the previous WHMIS 1988 regulation, were back on the docket, and open for public comment until November 2017. As you’ll recall, Health Canada once required that ingredient concentrations be declared using specified or “prescribed” ranges, which were required to be used anytime an ingredient’s concentration varied. However, industry ended up abusing the intent, by using these prescribed ranges as an alternative way of protecting confidential business information (CBI), without filing an application for exemption from disclosure under the Hazardous Materials Information Review Act (HMIRA). These specified ranges were therefore proposed to be removed from the Hazardous Products Regulations (HPR), which enters into force on June 1, 2018, and which would have forced manufacturers or importers to file an HMIRA claim (to the tune of $1800 CAD per claim) to use a prescribed concentration range to protect their CBI.

What’s Changing

Prescribed concentrations ranges are back! Not only are they back, but they cost nothing to use, since the recent amendments to the HPR now allow manufacturers/importers to incorporate prescribed concentration ranges on their SDS without having to file an HMIRA application. Note, however, that if you wish to use a generic range other than one of those prescribed in the HPR, you will indeed be required to file an HMIRA application and pay the fee of $1800 CAD; same story if you wish to withhold the name of an ingredient as trade secret.

Implications

Savings to industry from the reintroduction of prescribed concentration ranges will be substantial, since industry will now be permitted to protect confidentiality without having to pay $1,800 CAD per HMIRA submission. On the other hand, those wishing to protect confidentiality in Canada, will now need to revise their SDSs previously authored without the use of the prescribed concentration ranges, in order to update the concentrations to those required in the amendment. Enterprises placing products on the market in Canada are wise to begin exploring automated, software-driven solutions, so that these changes can be made as seamlessly as possible.

Close Menu